UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Does Block Play Improve Language Acquisition: A Randomized Trial

Not Applicable

Completed

Conditions: Healthy

First Posted Date: 2007-01-30

Last Posted Date: 2008-09-29

Lead Sponsor: University of Washington

Target Recruit Count: 200

Registration Number: NCT00428376

Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

Phase 3

Terminated

Conditions: HIV Infections

Interventions: Drug: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)
Drug: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)
Drug: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)
Drug: d4T/3TC/ABC (stavudine/lamivudine/abacavir)
Drug: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)
Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
Drug: ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)

First Posted Date: 2007-01-29

Last Posted Date: 2018-08-27

Lead Sponsor: University of Washington

Target Recruit Count: 34

Registration Number: NCT00427297

Locations: 🇰🇪
Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya

Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

Not Applicable

Terminated

Conditions: HIV Infections

Interventions: Drug: HAART

First Posted Date: 2007-01-29

Last Posted Date: 2018-07-26

Lead Sponsor: University of Washington

Target Recruit Count: 140

Registration Number: NCT00428116

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2007-01-23

Last Posted Date: 2013-05-06

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT00425646

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Phase 1

Completed

Conditions: Stage IIIC Breast Cancer
Stage IV Breast Cancer
Male Breast Cancer
Recurrent Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Biological: ONTAK
Other: flow cytometry
Other: immunohistochemistry staining method
Other: enzyme-linked immunosorbent assay
Other: laboratory biomarker analysis
Genetic: protein expression analysis

First Posted Date: 2007-01-23

Last Posted Date: 2018-12-05

Lead Sponsor: University of Washington

Target Recruit Count: 15

Registration Number: NCT00425672

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer

Phase 2

Completed

Conditions: Musculoskeletal Complications
Recurrent Breast Cancer
Stage II Breast Cancer
Arthralgia
Pain
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage I Breast Cancer

Interventions: Drug: letrozole
Dietary Supplement: calcium carbonate
Other: laboratory biomarker analysis
Dietary Supplement: calcium citrate
Dietary Supplement: calcium glucarate
Drug: calcium gluconate
Dietary Supplement: cholecalciferol
Procedure: assessment of therapy complications
Procedure: musculoskeletal complications management/prevention

First Posted Date: 2006-12-28

Last Posted Date: 2017-07-11

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT00416715

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 2

Completed

Conditions: Stage III Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Oropharynx
Stage III Squamous Cell Carcinoma of the Hypopharynx
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Larynx
Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Squamous Cell Carcinoma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: erlotinib hydrochloride
Drug: cisplatin
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Procedure: quality-of-life assessment

First Posted Date: 2006-12-13

Last Posted Date: 2013-05-10

Lead Sponsor: University of Washington

Target Recruit Count: 204

Registration Number: NCT00410826

Locations: 🇺🇸
New Hanover Radiation Oncology Center, Wilmington, North Carolina, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

and more 6 locations

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Malignant Pleural Effusion
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: imatinib mesylate
Drug: paclitaxel

First Posted Date: 2006-12-07

Last Posted Date: 2017-04-25

Lead Sponsor: University of Washington

Target Recruit Count: 34

Registration Number: NCT00408460

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

Phase 2

Completed

Conditions: Stage IA Breast Cancer
Stage II Breast Cancer
Stage IIIC Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer
Stage IIIB Breast Cancer